$CNTX News

Context drops bispecific T-cell engager on cost-cutting initiative

Context Therapeutics Stock (CNTX) is Falling After Hours: Here's What's Driving the Move

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

Context Therapeutics Q2 EPS $(0.15) Misses $(0.09) Estimate

Context Therapeutics Receives Nasdaq Noncompliance Notice, Gets Time Through Jan. 25 To Regain Compliance

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes

Context Therapeutics Added To Russell 2000, Russell 3000 Indexes, Effective June 26

Maxim Says Context Therapeutics (CNTX)’s Share Pullback Is an Overreaction; Remains Bullish

Maxim Group Maintains Buy on Context Therapeutics, Lowers Price Target to $4

CNTX Hits Worst Day In History After Ovarian Cancer Trial Data — But Analysts See Buying Opportunity In Dip

Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study

Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study

Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76

Context Therapeutics Announces Interim Phase 1 Clinical Data For CLDN6 X CD3 T Cell Engaging Bispecific Antibody, CTIM-76, In Advanced, Late-Line Platinum-Resistant Ovarian Cancer

Context Therapeutics to Present at the Jefferies Global Healthcare Conference

Context Therapeutics Reports First Quarter 2026 Operating and Financial Results

Context Therapeutics Q1 EPS $(0.09) Beats $(0.12) Estimate

Positive Signs As Multiple Insiders Buy Context Therapeutics Stock

Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer